Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas

Wayne F. Flintoff, Heather Sadlish, Richard Gorlick, Rui Yang, Frederick M R Williams

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Osteosarcomas are common primary malignant bone tumors that do not respond to conventional low-dose treatments of methotrexate (Mtx), suggesting an intrinsic resistance to this drug. Previous work has shown that cDNAs generated from osteosarcoma mRNA from a fraction of patients contain sequence changes in the reduced folate carrier (RFC), the membrane protein transporter for Mtx. In this study, the functionality of the altered RFC proteins was assessed by fusing the green fluorescent protein (GFP) to the C-terminal, and examining the ability of the transfected constructs to complement a hamster cell line null for the carrier. Confocal microscopy and cell surface biotinylation indicated that all altered proteins were properly localized at the cell membrane. Only one of those examined, Leu291Pro, was unable to complement the null carrier line, but did bind Mtx at the cell surface. Thus, this alteration confers drug resistance since the carrier is unable to translocate the substrate across the cell membrane. Three alterations, Ser46Asn, Ser4Pro and Gly259Trp, while able to complement the carrier null line, conferred some degree of resistance to Mtx via a decreased rate of transport (Vmax). Another set of alterations, Glu21Lys, Ala7Val, and the combined changes Thr222Ile, Met254Thr, complemented the carrier null line and did not confer resistance to Mtx. Thus, some, but not all of these identified alterations in the RFC may contribute to the lack of responsiveness of osteosarcomas to Mtx treatment.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1690
Issue number2
DOIs
StatePublished - Oct 14 2004
Externally publishedYes

Fingerprint

Reduced Folate Carrier Protein
Osteosarcoma
Methotrexate
Drug Resistance
Cell Membrane
Biotinylation
Membrane Transport Proteins
Protein C
Green Fluorescent Proteins
Confocal Microscopy
Cricetinae
Membrane Proteins
Complementary DNA
Bone and Bones
Cell Line
Messenger RNA
Therapeutics

Keywords

  • (E) GFP
  • (enhanced) green fluorescent protein
  • Biotin succinimide, sulfo-NHS-SS biotin
  • Biotinylation
  • Fusion protein
  • HRP
  • Methotrexate
  • Osteosarcomas
  • Reduced folate carrier
  • sulfosuccinimidyl-2- (biotinamido) ethyl-1,3-dithiopropionate

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Biophysics

Cite this

Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. / Flintoff, Wayne F.; Sadlish, Heather; Gorlick, Richard; Yang, Rui; Williams, Frederick M R.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1690, No. 2, 14.10.2004, p. 110-117.

Research output: Contribution to journalArticle

Flintoff, Wayne F. ; Sadlish, Heather ; Gorlick, Richard ; Yang, Rui ; Williams, Frederick M R. / Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2004 ; Vol. 1690, No. 2. pp. 110-117.
@article{5217cb162f8449c28517743a2d1c6961,
title = "Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas",
abstract = "Osteosarcomas are common primary malignant bone tumors that do not respond to conventional low-dose treatments of methotrexate (Mtx), suggesting an intrinsic resistance to this drug. Previous work has shown that cDNAs generated from osteosarcoma mRNA from a fraction of patients contain sequence changes in the reduced folate carrier (RFC), the membrane protein transporter for Mtx. In this study, the functionality of the altered RFC proteins was assessed by fusing the green fluorescent protein (GFP) to the C-terminal, and examining the ability of the transfected constructs to complement a hamster cell line null for the carrier. Confocal microscopy and cell surface biotinylation indicated that all altered proteins were properly localized at the cell membrane. Only one of those examined, Leu291Pro, was unable to complement the null carrier line, but did bind Mtx at the cell surface. Thus, this alteration confers drug resistance since the carrier is unable to translocate the substrate across the cell membrane. Three alterations, Ser46Asn, Ser4Pro and Gly259Trp, while able to complement the carrier null line, conferred some degree of resistance to Mtx via a decreased rate of transport (Vmax). Another set of alterations, Glu21Lys, Ala7Val, and the combined changes Thr222Ile, Met254Thr, complemented the carrier null line and did not confer resistance to Mtx. Thus, some, but not all of these identified alterations in the RFC may contribute to the lack of responsiveness of osteosarcomas to Mtx treatment.",
keywords = "(E) GFP, (enhanced) green fluorescent protein, Biotin succinimide, sulfo-NHS-SS biotin, Biotinylation, Fusion protein, HRP, Methotrexate, Osteosarcomas, Reduced folate carrier, sulfosuccinimidyl-2- (biotinamido) ethyl-1,3-dithiopropionate",
author = "Flintoff, {Wayne F.} and Heather Sadlish and Richard Gorlick and Rui Yang and Williams, {Frederick M R}",
year = "2004",
month = "10",
day = "14",
doi = "10.1016/j.bbadis.2004.05.008",
language = "English (US)",
volume = "1690",
pages = "110--117",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas

AU - Flintoff, Wayne F.

AU - Sadlish, Heather

AU - Gorlick, Richard

AU - Yang, Rui

AU - Williams, Frederick M R

PY - 2004/10/14

Y1 - 2004/10/14

N2 - Osteosarcomas are common primary malignant bone tumors that do not respond to conventional low-dose treatments of methotrexate (Mtx), suggesting an intrinsic resistance to this drug. Previous work has shown that cDNAs generated from osteosarcoma mRNA from a fraction of patients contain sequence changes in the reduced folate carrier (RFC), the membrane protein transporter for Mtx. In this study, the functionality of the altered RFC proteins was assessed by fusing the green fluorescent protein (GFP) to the C-terminal, and examining the ability of the transfected constructs to complement a hamster cell line null for the carrier. Confocal microscopy and cell surface biotinylation indicated that all altered proteins were properly localized at the cell membrane. Only one of those examined, Leu291Pro, was unable to complement the null carrier line, but did bind Mtx at the cell surface. Thus, this alteration confers drug resistance since the carrier is unable to translocate the substrate across the cell membrane. Three alterations, Ser46Asn, Ser4Pro and Gly259Trp, while able to complement the carrier null line, conferred some degree of resistance to Mtx via a decreased rate of transport (Vmax). Another set of alterations, Glu21Lys, Ala7Val, and the combined changes Thr222Ile, Met254Thr, complemented the carrier null line and did not confer resistance to Mtx. Thus, some, but not all of these identified alterations in the RFC may contribute to the lack of responsiveness of osteosarcomas to Mtx treatment.

AB - Osteosarcomas are common primary malignant bone tumors that do not respond to conventional low-dose treatments of methotrexate (Mtx), suggesting an intrinsic resistance to this drug. Previous work has shown that cDNAs generated from osteosarcoma mRNA from a fraction of patients contain sequence changes in the reduced folate carrier (RFC), the membrane protein transporter for Mtx. In this study, the functionality of the altered RFC proteins was assessed by fusing the green fluorescent protein (GFP) to the C-terminal, and examining the ability of the transfected constructs to complement a hamster cell line null for the carrier. Confocal microscopy and cell surface biotinylation indicated that all altered proteins were properly localized at the cell membrane. Only one of those examined, Leu291Pro, was unable to complement the null carrier line, but did bind Mtx at the cell surface. Thus, this alteration confers drug resistance since the carrier is unable to translocate the substrate across the cell membrane. Three alterations, Ser46Asn, Ser4Pro and Gly259Trp, while able to complement the carrier null line, conferred some degree of resistance to Mtx via a decreased rate of transport (Vmax). Another set of alterations, Glu21Lys, Ala7Val, and the combined changes Thr222Ile, Met254Thr, complemented the carrier null line and did not confer resistance to Mtx. Thus, some, but not all of these identified alterations in the RFC may contribute to the lack of responsiveness of osteosarcomas to Mtx treatment.

KW - (E) GFP

KW - (enhanced) green fluorescent protein

KW - Biotin succinimide, sulfo-NHS-SS biotin

KW - Biotinylation

KW - Fusion protein

KW - HRP

KW - Methotrexate

KW - Osteosarcomas

KW - Reduced folate carrier

KW - sulfosuccinimidyl-2- (biotinamido) ethyl-1,3-dithiopropionate

UR - http://www.scopus.com/inward/record.url?scp=4644251592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644251592&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2004.05.008

DO - 10.1016/j.bbadis.2004.05.008

M3 - Article

C2 - 15469899

AN - SCOPUS:4644251592

VL - 1690

SP - 110

EP - 117

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 2

ER -